Would CMS’s Drug Pricing Transparency Requirement Really Lower Prices?

Thought Leader:

Ian Spatz JD, MPA, Senior Advisor, Manatt Health

October 25, 2018

On October 15, the Trump Administration’s Center for Medicare and Medicaid Services, CMS, published a proposed rule that, if finalized, would require prescription drug makers to include prescription drug price information in broadcast advertising. The Administration stated that it believes including the prices in ads will help consumers make better choices and, ultimately, save money for the Medicare and Medicaid programs.

In this podcast, we will explore what this proposal means and what it might do with Ian Spatz of Manatt Health.

You can also read a related white paper on this topic using the link below.

Length: 23:02       Size: 10.5MB

Post a Comment

You must be logged in to post a Comment.

FEEDBACK